AnGes,Inc. (4563.T) Latest Company News

Aug 17, 2026, 04:08 UTC
AnGes announced progress on its HGF gene therapy product, having completed clinical trials in the US and moving to the preparation stage for a Biologics License Application (BLA) submission to the FDA, with a plan for staged submission without a Pre-BLA Meeting.
Source:
- s.kabutan.jp
Aug 17, 2026, 04:08 UTC
AnGes resolved to issue the 47th and 48th share subscription rights and the 2nd unsecured convertible bond-type share subscription rights bonds, allocating them to a fund managed by Growth Partners, to raise a total of 8.5 billion yen, and also entered into a business alliance agreement with the same fund.
Source:
- s.kabutan.jp
Aug 16, 2026, 20:45 UTC
Anges Inc. announced the issuance of 2 billion yen in convertible bonds (CB) with a conversion price of 43.5 yen, fully allocated to a GP fund.
Source:
- s.kabutan.jp
Aug 14, 2026, 08:15 UTC
Anges Inc. reported its second-quarter 2026 results on August 14, 2026, with a consolidated net loss of 16.3 billion yen for April-June, narrowing from a 27.1 billion yen loss a year earlier.
Source:
- s.kabutan.jp
Aug 14, 2026, 08:15 UTC
Anges Inc. reported its first-half 2026 results on August 14, 2026, with a consolidated net loss of 27.1 billion yen for January-June, narrowing from a 39.6 billion yen loss a year earlier.
Source:
- s.kabutan.jp
- s.kabutan.jp
Jul 17, 2026, 00:34 UTC
Anges announced it will proceed with filing a Biologics License Application (BLA) for its HGF gene therapy product in the United States after receiving a positive response from the FDA during pre-BLA meeting correspondence.
Source:
- s.kabutan.jp

4563.T

AnGes announced progress on its HGF gene therapy product, having completed clinical trials in the US and moving to the preparation stage for a Biologics License Application (BLA) submission to the FDA, with a plan for staged submission without a Pre-BLA Meeting.

Anges Inc. announced the issuance of 2 billion yen in convertible bonds (CB) with a conversion price of 43.5 yen, fully allocated to a GP fund.

Anges Inc. reported its second-quarter 2026 results on August 14, 2026, with a consolidated net loss of 16.3 billion yen for April-June, narrowing from a 27.1 billion yen loss a year earlier.

Anges Inc. reported its first-half 2026 results on August 14, 2026, with a consolidated net loss of 27.1 billion yen for January-June, narrowing from a 39.6 billion yen loss a year earlier.

Anges announced it will proceed with filing a Biologics License Application (BLA) for its HGF gene therapy product in the United States after receiving a positive response from the FDA during pre-BLA meeting correspondence.